Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Bogdan Ionel Vatu, Stefan-Alexandru Artene, Adeline-Georgiana Staicu, Adina Turcu-Stiolica, Catalin Folcuti, Alexandra Dragoi, Catalina Cioc, Stefania-Carina Baloi, Ligia Gabriela Tataranu, Cristian Silosi & Anica Dricu. (2019) Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review. Journal of Immunoassay and Immunochemistry 40:1, pages 70-80.
Read now
Read now
Aladine A. Elsamadicy, Pakawat Chongsathidkiet, Rupen Desai, Karolina Woroniecka, S. Harrison Farber, Peter E. Fecci & John H. Sampson. (2017) Prospect of rindopepimut in the treatment of glioblastoma. Expert Opinion on Biological Therapy 17:4, pages 507-513.
Read now
Read now
Neha Kamran, Alexandra Calinescu, Marianela Candolfi, Mayuri Chandran, Yohei Mineharu, Antonela S. Asad, Carl Koschmann, Felipe J. Nunez, Pedro R. Lowenstein & Maria G. Castro. (2016) Recent advances and future of immunotherapy for glioblastoma. Expert Opinion on Biological Therapy 16:10, pages 1245-1264.
Read now
Read now
Abid H. Banday, Salika Jeelani & Victor J. Hruby. (2015) Cancer vaccine adjuvants – recent clinical progress and future perspectives. Immunopharmacology and Immunotoxicology 37:1, pages 1-11.
Read now
Read now
Claire Faulkner, Abigail Palmer, Hannah Williams, Christopher Wragg, Harry R. Haynes, Paul White, Ruth-Mary DeSouza, Maggie Williams, Kirsten Hopkins & Kathreena M. Kurian. (2015) EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. British Journal of Neurosurgery 29:1, pages 23-29.
Read now
Read now
Jasmina S Redzic, Timothy H Ung & Michael W Graner. (2014) Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmacogenomics and Personalized Medicine 7, pages 65-77.
Read now
Read now
Kristen A Batich & John H Sampson. (2014) Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opinion on Pharmacotherapy 15:14, pages 2047-2061.
Read now
Read now
Raffaele Addeo, Silvia Zappavigna, Ciro Parlato & Michele Caraglia. (2014)
Erlotinib: early clinical development in brain cancer. Expert Opinion on Investigational Drugs 23:7, pages 1027-1037.
Read now
Read now
Derek A Wainwright, Pragati Nigam, Bart Thaci, Mahua Dey & Maciej S Lesniak. (2012) Recent developments on immunotherapy for brain cancer. Expert Opinion on Emerging Drugs 17:2, pages 181-202.
Read now
Read now
Carmen Balañá, Salvador Villá & Pilar Teixidor. (2011) Evolution of care for patients with relapsed glioblastoma. Expert Review of Anticancer Therapy 11:11, pages 1719-1729.
Read now
Read now
Alia Hdeib & Andrew E Sloan. (2011) Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opinion on Biological Therapy 11:6, pages 799-806.
Read now
Read now
Fei Ye, Qinglei Gao & Ming-Jun Cai. (2010) Therapeutic targeting of EGFR in malignant gliomas. Expert Opinion on Therapeutic Targets 14:3, pages 303-316.
Read now
Read now
Articles from other publishers (46)
Fenge Li, Huancheng Wu, Xueming Du, Yimo Sun, Barbara Nassif Rausseo, Amjad Talukder, Arjun Katailiha, Lama Elzohary, Yupeng Wang, Zhiyu Wang & Gregory Lizée. (2023) Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma. Vaccines 11:9, pages 1460.
Crossref
Crossref
Szymon Grochans, Anna Maria Cybulska, Donata Simińska, Jan Korbecki, Klaudyna Kojder, Dariusz Chlubek & Irena Baranowska-Bosiacka. (2022) Epidemiology of Glioblastoma Multiforme–Literature Review. Cancers 14:10, pages 2412.
Crossref
Crossref
Radhika Thokala, Zev A. Binder, Yibo Yin, Logan Zhang, Jiasi Vicky Zhang, Daniel Y. Zhang, Michael C. Milone, Guo-li Ming, Hongjun Song & Donald M. O’Rourke. (2021) High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology 11.
Crossref
Crossref
Yaning Wang, Wanqi Chen, Yixin Shi, Chengrui Yan, Ziren Kong, Yuekun Wang, Yu Wang & Wenbin Ma. (2021) Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. Frontiers in Oncology 11.
Crossref
Crossref
Ian E. McCutcheon & Mark C. Preul. (2021) Historical Perspective on Surgery and Survival with Glioblastoma: How Far Have We Come?. World Neurosurgery 149, pages 148-168.
Crossref
Crossref
Pankaj K. Singh, Anup K. Srivastava, Atul Dev, Babita Kaundal, Subhasree Roy Choudhury & Surajit Karmakar. (2018) 1, 3β-Glucan anchored, paclitaxel loaded chitosan nanocarrier endows enhanced hemocompatibility with efficient anti-glioblastoma stem cells therapy. Carbohydrate Polymers 180, pages 365-375.
Crossref
Crossref
Manfred Westphal, Cecile L. Maire & Katrin Lamszus. (2017) EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. CNS Drugs 31:9, pages 723-735.
Crossref
Crossref
Nakho Chang, Sun Hee Ahn, Doo-Sik Kong, Hye Won Lee & Do-Hyun Nam. (2017) The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Molecular and Cellular Endocrinology 451, pages 53-65.
Crossref
Crossref
Sunil Thomas, Jacques Izard, Emily Walsh, Kristen Batich, Pakawat Chongsathidkiet, Gerard Clarke, David A. Sela, Alexander J. Muller, James M. Mullin, Korin Albert, John P. Gilligan, Katherine DiGuilio, Rima Dilbarova, Walker Alexander & George C. Prendergast. (2017) The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Research 77:8, pages 1783-1812.
Crossref
Crossref
Yung-Chih Kuo & I-Hsuan Lee. (2016) Delivery of doxorubicin to glioblastoma multiforme in vitro using solid lipid nanoparticles with surface aprotinin and melanotransferrin antibody for enhanced chemotherapy. Journal of the Taiwan Institute of Chemical Engineers 61, pages 32-45.
Crossref
Crossref
Anirudh Saraswathula, Elizabeth A. Reap, Bryan D. Choi, Robert J. Schmittling, Pamela K. Norberg, Elias J. Sayour, James E. Herndon, Patrick Healy, Kendra L. Congdon, Gerald E. Archer, Luis Sanchez-Perez & John H. Sampson. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology, Immunotherapy 65:2, pages 205-211.
Crossref
Crossref
Nadia Pasinetti, Luigi Pirtoli, Michela Buglione, Luca Triggiani, Paolo Borghetti, Paolo Tini & Stefano Maria Magrini. 2016. Radiobiology of Glioblastoma. Radiobiology of Glioblastoma
275
292
.
John H. Sampson & Duane A. Mitchell. (2015) Vaccination strategies for neuro-oncology: Table 1.. Neuro-Oncology 17:suppl 7, pages vii15-vii25.
Crossref
Crossref
Payal A. Shah & John Goldberg. (2015) Novel Approaches to Pediatric Cancer: Immunotherapy. AIMS Medical Science 2:2, pages 104-117.
Crossref
Crossref
Orin Bloch. 2015. Current Understanding and Treatment of Gliomas. Current Understanding and Treatment of Gliomas
143
158
.
Xiang Yi, Devika S. Manickam, Anna Brynskikh & Alexander V. Kabanov. (2014) Agile delivery of protein therapeutics to CNS. Journal of Controlled Release 190, pages 637-663.
Crossref
Crossref
Pedro R. LowensteinMaria G. Castro. (2014) The Value of EGFRvIII as the Target for Glioma Vaccines. American Society of Clinical Oncology Educational Book:34, pages 42-50.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology
371
391
.
B. M. Alexander, P. Y. Wen, L. Trippa, D. A. Reardon, W.-K. A. Yung, G. Parmigiani & D. A. Berry. (2013) Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro-Oncology 15:8, pages 972-978.
Crossref
Crossref
Vidyalakshmi Chandramohan, Duane A Mitchell, Laura A Johnson, John H Sampson & Darell D Bigner. (2013) Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology 9:7, pages 977-990.
Crossref
Crossref
Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich & Stefan Stevanović. (2012) Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. Journal of Neuro-Oncology 111:3, pages 285-294.
Crossref
Crossref
Sean E. Lawler & E. Antonio Chiocca. 2013. Genomic and Personalized Medicine. Genomic and Personalized Medicine
749
764
.
Kirti Gupta & Pravin Salunke. (2012) Molecular markers of glioma: an update on recent progress and perspectives. Journal of Cancer Research and Clinical Oncology 138:12, pages 1971-1981.
Crossref
Crossref
Li‐li Zhao, Kan‐lun Xu, Shan‐wei Wang, Bai‐lai Hu & Li‐rong Chen. (2012) Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology 61:4, pages 726-736.
Crossref
Crossref
Gavin P. Dunn, Peter E. Fecci & William T. Curry. (2012) Cancer Immunoediting in Malignant Glioma. Neurosurgery 71:2, pages 201-223.
Crossref
Crossref
Christopher Jackson, Jacob Ruzevick, Anubhav G. Amin & Michael Lim. (2012) Potential Role for STAT3 Inhibitors in Glioblastoma. Neurosurgery Clinics of North America 23:3, pages 379-389.
Crossref
Crossref
Alissa A. Thomas, Marc S. Ernstoff & Camilo E. Fadul. (2012) Immunotherapy for the Treatment of Glioblastoma. The Cancer Journal 18:1, pages 59-68.
Crossref
Crossref
Roger J. Packer, Tobey J. MacDonald & Gilbert Vezina. 2012. Swaiman's Pediatric Neurology. Swaiman's Pediatric Neurology
1339
1387
.
Allison M. Cushman-Vokoun. 2012. Molecular Genetics and Personalized Medicine. Molecular Genetics and Personalized Medicine
51
101
.
Gwendalyn D King, AKM Ghulam Muhammad, Daniel Larocque, Kyle R Kelson, Weidong Xiong, Chunyan Liu, Nicholas SR Sanderson, Kurt M Kroeger, Maria G Castro & Pedro R Lowenstein. (2011) Combined Flt3L/TK Gene Therapy Induces Immunological Surveillance Which Mediates an Immune Response Against a Surrogate Brain Tumor Neoantigen. Molecular Therapy 19:10, pages 1793-1801.
Crossref
Crossref
Marina N. Nikiforova & Ronald L. Hamilton. (2011) Molecular Diagnostics of Gliomas. Archives of Pathology & Laboratory Medicine 135:5, pages 558-568.
Crossref
Crossref
Rolando Perez, Ernesto Moreno, Greta Garrido & Tania Crombet. (2011) EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 3:2, pages 2014-2031.
Crossref
Crossref
Colin D. Medley, Suwussa Bamrungsap, Weihong Tan & Joshua E. Smith. (2011) Aptamer-Conjugated Nanoparticles for Cancer Cell Detection. Analytical Chemistry 83:3, pages 727-734.
Crossref
Crossref
A. Kantele, M. P. Häkkinen, J. Zivny, C. O. Elson, J. Mestecky & J. M. Kantele. (2011) Humoral Immune Response to Keyhole Limpet Haemocyanin, the Protein Carrier in Cancer Vaccines. Clinical and Developmental Immunology 2011, pages 1-6.
Crossref
Crossref
Michelle J Hickey, Colin C Malone, Kate L Erickson, Martin R Jadus, Robert M Prins, Linda M Liau & Carol A Kruse. (2010) Cellular and vaccine therapeutic approaches for gliomas. Journal of Translational Medicine 8:1.
Crossref
Crossref
Pedro R. Lowenstein. (2010) Cancer Vaccines in Glioma: How to Balance the Challenges of Small Trials, Efficiency, and Potential Adverse Events. Journal of Clinical Oncology 28:31, pages 4670-4673.
Crossref
Crossref
Isaac Yang, Tarik Tihan, Seunggu J. Han, Margaret R. Wrensch, John Wiencke, Michael E. Sughrue & Andrew T. Parsa. (2010) CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. Journal of Clinical Neuroscience 17:11, pages 1381-1385.
Crossref
Crossref
Markus J. Riemenschneider, Judith W. M. Jeuken, Pieter Wesseling & Guido Reifenberger. (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica 120:5, pages 567-584.
Crossref
Crossref
Leopold Arko, Igor Katsyv, Grace E. Park, William Patrick Luan & John K. Park. (2010) Experimental approaches for the treatment of malignant gliomas. Pharmacology & Therapeutics 128:1, pages 1-36.
Crossref
Crossref
Michael Weller, Wolfgang Wick, Monika E Hegi, Roger Stupp & Ghazaleh Tabatabai. (2010) Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology 6:9, pages 1407-1414.
Crossref
Crossref
Michael J. Ciesielski, Manmeet S. Ahluwalia, Stephan A. Munich, Molly Orton, Tara Barone, Asher Chanan-Khan & Robert A. Fenstermaker. (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunology, Immunotherapy 59:8, pages 1211-1221.
Crossref
Crossref
Mariana Puntel, A. K. M. G. Muhammad, Marianela Candolfi, Alireza Salem, Kader Yagiz, Catherine Farrokhi, Kurt M. Kroeger, Weidong Xiong, James F. Curtin, Chunyan Liu, Niyati S. Bondale, Jonathan Lerner, Robert N. Pechnick, Donna Palmer, Philip Ng, Pedro R. Lowenstein & Maria G. Castro. (2010) A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics. Journal of Virology 84:12, pages 6007-6017.
Crossref
Crossref
Thomas W. DubenskyJrJr & Steven G. Reed. (2010) Adjuvants for cancer vaccines. Seminars in Immunology 22:3, pages 155-161.
Crossref
Crossref
Erin Dunbar & Anthony T. Yachnis. (2010) Glioma Diagnosis: Immunohistochemistry and Beyond. Advances in Anatomic Pathology 17:3, pages 187-201.
Crossref
Crossref
M. Weller. (2010) Immunotherapy for glioblastoma: a long and winding road. Neuro-Oncology 12:4, pages 319-319.
Crossref
Crossref
Lisheng Ge, Neil Hoa, Daniela A. Bota, Josephine Natividad, Andrew Howat & Martin R. Jadus. (2010) Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions. Clinical and Developmental Immunology 2010, pages 1-19.
Crossref
Crossref